Limitations of Capivasertib
As an AKT kinase inhibitor, the clinical application of Capivasortib requires strict adherence to specific restrictions, including contraindications for special populations, drug interaction management, and safety monitoring requirements, to ensure that treatment benefits outweigh risks.
1. Special population restrictions
(1) Pregnancy: May cause fetal damage. Women of childbearing age should take effective contraceptive measures during treatment and within one week after discontinuing medication
(2) Breastfeeding period: Medications may be secreted through breast milk. Breastfeeding is prohibited during the medication period and within 7 days after the last administration
(3) Liver dysfunction: Patients with moderate to severe liver dysfunction should use it with caution and dosage adjustment is recommended
2 drug interactions
(1) Strong CYP3A4 inhibitor: Avoid combination therapy as it may significantly increase the blood concentration of capecitabine
(2) CYP3A4 inducer: may reduce efficacy, alternative treatment options need to be considered
(3) Narrow therapeutic window medication: It is necessary to closely monitor the concentration of drugs such as warfarin to prevent an increased risk of bleeding
3 Safety monitoring requirements
(1) Blood glucose monitoring: regular monitoring before and during treatment, especially for patients with diabetes, management should be strengthened
(2) Electrocardiogram examination: Evaluate QT interval at baseline and during treatment, avoid combination with other QT prolonging drugs
(3) Skin toxicity: Severe rash requires interruption of treatment and permanent discontinuation of medication if necessary
4 Medication restrictions
(1) Dose adjustment: If there are ≥ grade 3 adverse reactions, the medication should be suspended and reduced according to the level after recovery
(2) Medication plan: Strictly follow the 4-day medication/3-day interval cycle, and do not take continuously every day
(3) Swallowing requirements: Swallow the entire tablet, do not crush or chew to avoid affecting drug release
Disclaimer：《Limitations of Capivasertib》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！